EANS-Adhoc: LifeWatch V: State-of-the-art smartphone with healthcare capabilities empowering patients and consumers (with document)

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

New Products/LifeWatch V Smart Phone

27.06.2012

Neuhausen am Rheinfall / Switzerland - LifeWatch AG (SIX Swiss
Exchange: LIFE), the leading wireless cardiac monitoring service and
home sleep test provider in the U.S., presents today LifeWatch V, the
world's first-of-its-kind healthcare smartphone. The fully featured
state-of-the-art smartphone allows patients as well as health- and
wellbeing-conscious consumers to self-operate a wide range of highly
valuable embedded medical sensors, wellness-related applications,
cloud-based services and 24/7 call center support.

You will find a PDF-Version of this press release at the end of this
message.

As a next step of its product and geographical diversification
LifeWatch presents today LifeWatch V, the world's first fully
featured smartphone which operates on an android OS. The
state-of-the-art solution offers multiple sophisticated embedded
medical miniature sensors, wellness-related applications, cloud-based
services and 24/7 call center support. By using the barely visible
sensors on the phone's frame, patients as well as health- and
wellbeing conscious consumers can track, capture, collect and analyze
their health and medical measurements anywhere anytime. The features
include ECG, body temperature, blood glucose, heart rate, blood
oxygen saturation, body fat percentage and stress levels (heart rate
variability). All collected data can be retrieved from the cloud for
a follow-up anytime anywhere. Users can thus take corrective action,
plan their diets and activities, securely share the information with
a health provider or family member, trend and analyze the data and
more. Patients are also able to program the unit to remind them of
their drug type, dose and intake time.

LifeWatch V with add-on service offering:

LifeWatch V was designed with a flexible service-product ecosystem in
mind, allowing easy integration of services. The LifeWatch V handset
unit includes a service enablement platform to support the
transmission of medical data to be analyzed, evaluated and
communicated to health professionals and call center personnel around
the clock. The device wirelessly interacts with a cloud-based
environment allowing users direct access to a wide range of valuable
complementary medical and wellness related services.

Strategic alliances with local partners:

Smartphones are positioned to overtake many computing functions that
were reserved to computers alone. More importantly, the smartphone
has emerged as an intimate device consumers carry with them anywhere
and anytime, making it an ideal vehicle to let users self-test their
health, especially users with an interest in the medical field.
Recent market developments have witnessed the emergence of
health-dedicated cellular phones.

Based on a full and complete Go-to-Market analysis LifeWatch intends
to launch the healthcare solution smartphone world-wide. In the
initial markets LifeWatch has identified several local partners to
enter into strategic partnerships.

|LifeWatch V: Medical specifications
|
|EKG (1-Lead) |EKG dynamic range 0.15-5 mV.
|
| |Frequency response 0.5-40 Hz.
|
| |Sampling 12 bit, 250 samples /sec.
|
| |Test time: Average of 35 sec.
|
|Heart rate |HF measurement range 30 to 250 bpm
|
| |QRS detection sensitivity > 98%
|
| |QRS detection predictability > 98%
|
| |Result time: Average of 10 sec.
|
|SpO2 |Method: Reflective R & IR emission
|
| |Oxygen saturation range: 70 to 100%
|
| |Accuracy: Standard deviation ± 1 digits
|
| |Test time: Average of 20 sec.
|
|Glucose |Range: 10-650 mg/dl
|
| |Sample size: 0,4-0,7 ?L
|
| |Accuracy: ± 10 mg/dL for glucose level < 75
mg/dL|
| |
|
| |12.5% for glucose level => 75 mg/dL
|
| |Test time: 3-5 sec.
|
|IR-Thermometer |Range: 34 to 41 C°; Accuracy: ± 0,2 C°
|
|Body fat percentage |Method: Bioelectrical Impedance
|
|Operating temperature |10 to 40 C° (40 to 104 °F)
|

LifeWatch V: Technical specifications |
|Network |3G 850/1900/2100; 2G 850/900/1800/1900; 3G
|
| |(HSDPA, 7.2 Mbps)
|
|Operating system |Android 2.3 (Gingerbread)
|
|Processor |Qualcomm MSM7227Turbo
|
|Weight and dimensions (HxWxD)|162g; 132(mm) x 70.8(mm) x 13.2(mm)
|
|Display |LCD 4.3" 480*480 Pixels (WVGA)
|
|Battery capacity- |1500 mAh
|
|Camera |5MP main camera + 300KP front camera
|
|Connectivity |Bluetooth Ver. 2.1 with BT/Wi-Fi-coexistence
|
| |Wi-Fi IEEE 802.11b/g/n
|
|Memory |1GB Flash, 512MB RAM, T-Flash, Micro SD Slot (up
|
| |to 32GB)
|
|Certification |CE- Mark pending
|
|Features |GPS, A-GPS supported
|

Don't miss it: Join us for a live presentation of LifeWatch V today:

Live demonstration: June 27, 2012, 3:30 p.m., Zurich, Metropol,
Fraumünsterstrasse 12;

Live Video Webcast in the IR section on www.lifewatch.com
Product website: http://www.lifewatchv.com/demo/

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote
patient monitoring services. LifeWatch services cater to individuals, ranging

from high-risk and chronically ill patients, to consumers of health
and wellness products. LifeWatch has subsidiaries in the United
States, the Netherlands, Japan, the United Kingdom, Switzerland and
Israel. LifeWatch AG is the parent company of LifeWatch Services
Inc., a leading US-based cardiac monitoring service provider, and
manufacturer of telecardiology products. LifeWatch is also
introducing a new program for Home Sleep Testing of Obstructive Sleep
Apnea (OSA) patients under the brand name NiteWatch. For additional
information, please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward- looking statements.
The words "believe," "may," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions are intended
to identify forward-looking statements. LifeWatch AG has based these
forward- looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward- looking statements. All forward-looking
statements are based only on data available to LifeWatch AG at the
time of the issue of this press release. LifeWatch AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/19lpaarY

Further inquiry note:
Sensus Investor and Public Relations GmbH, Zürich:
Tel+41 433665511 | Fax+41 43 366 55 12 | Email lifewatch@sensus.ch

end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/19lpaarY

issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English